Intrapatient dose escalation to 800 mg/m<sup>2</sup> pemetrexed is safe and feasible in patients with advanced non-small cell lung cancer (NSCLC) who have had prior chemotherapyJ. S. Lee, M. Lehnert, Cheng‐yan Yang et al.|Journal of Clinical Oncology|2005Cited by 0